Neurochemical Aspects Of Excitotoxicity

Leading researchers offer cutting-edge information on glutamate metabolism in the brain, examining the role of glutamate transporters and the involvement of glutamate receptors in the pathogenesis of acute neural trauma and neurodegenerative diseases. In addition, the authors discuss the treatment of these diseases with endogenous and exogenous antioxidants and glutamate receptor antagonists.

Collectively, neurodegenerative diseases are characterized by chronic and progressive loss of neurons in discrete areas of the brain, producing debilitating symptoms such as dementia, loss of memory, loss of sensory or motor capability, decreased overall quality of life eventually leading to premature death. Two types of cell death are known to occur during neurodegeneration: (a) apoptosis and (b) necrosis. The necrosis is characterized by the passive cell swelling, intense mitochondrial damage with rapid loss of ATP, alterations in neural membrane permeability, high calcium influx, and disruption of ion homeostasis. This type of cell death leads to membrane lysis and release of intracellular components that induce inflammatory reactions. Necrotic cell death normally occurs at the core of injury site. In contrast, apoptosis is an active process in which caspases (a group of endoproteases with specificity for aspartate residues in protein) are stimulated. Apoptotic cell death is accompanied by cell shrinkage, dynamic membrane blebbing, chromatin condensation, DNA laddering, loss of phospholipids asymmetry, low ATP levels, and mild calcium overload. This type of cell death normally occurs in penumbral region at the ischemic injury site and in different regions in various neurodegenerative diseases.

Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.

Traumatic brain injury (TBI) remains a significant source of death and permanent disability, contributing to nearly one-third of all injury related deaths in the United States and exacting a profound personal and economic toll. Despite the increased resources that have recently been brought to bear to improve our understanding of TBI, the development of new diagnostic and therapeutic approaches has been disappointingly slow. Translational Research in Traumatic Brain Injury attempts to integrate expertise from across specialties to address knowledge gaps in the field of TBI. Its chapters cover a wide scope of TBI research in five broad areas: Epidemiology Pathophysiology Diagnosis Current treatment strategies and sequelae Future therapies Specific topics discussed include the societal impact of TBI in both the civilian and military populations, neurobiology and molecular mechanisms of axonal and neuronal injury, biomarkers of traumatic brain injury and their relationship to pathology, neuroplasticity after TBI, neuroprotective and neurorestorative therapy, advanced neuroimaging of mild TBI, neurocognitive and psychiatric symptoms following mild TBI, sports-related TBI, epilepsy and PTSD following TBI, and more. The book integrates the perspectives of experts across disciplines to assist in the translation of new ideas to clinical practice and ultimately to improve the care of the brain injured patient.

"Neurodegenerative diseases are a complex heterogeneous group of diseases associated with site-specific premature and slow death of certain neuronal populations in brain and spinal cord tissues. For example, in Alzheimer disease, neuronal degeneration occu"

Basic Neurochemistry: Principles of Molecular, Cellular, and Medical Neurobiology, the outstanding and comprehensive classic text on neurochemistry, is now newly updated and revised in its Eighth Edition. For more than forty years, this text has been the worldwide standard for information on the biochemistry of the nervous system, serving as a resource for postgraduate trainees and teachers in neurology, psychiatry, and basic neuroscience, as well as for medical, graduate, and postgraduate students and instructors in the neurosciences. The text has evolved, as intended, with the science. It is also an excellent source of current information on basic biochemical and cellular processes in brain function and neurological diseases for continuing medical education and qualifying examinations. This text continues to be the standard reference and textbook for exploring the translational nature of neuroscience, bringing basic and clinical neuroscience together in one authoritative volume. Our book title reflects the expanded attention to these links between neurochemistry and neurologic disease. This new edition continues to cover the basics of neurochemistry as in the earlier editions, along with expanded and additional coverage of new research from: Intracellular trafficking; Stem cells, adult neurogenesis, regeneration; Lipid messengers; Expanded coverage of all major neurodegenerative and psychiatric disorders; Neurochemistry of addiction; Neurochemistry of pain; Neurochemistry of hearing and balance; Neurobiology of learning and memory; Sleep; Myelin structure, development, and disease; Autism; and Neuroimmunology. Completely updated text with new authors and material, and many entirely new chapters Over 400 fully revised figures in splendid color 61 chapters covering the range of cellular, molecular and medical neuroscience Translational science boxes emphasizing the connections between basic and clinical neuroscience Companion website at http://elsevierdirect.com/companions/9780123749475

The NMDA receptor plays a critical role in the development of the central nervous system and in adult neuroplasticity, learning, and memory. Therefore, it is not surprising that this receptor has been widely studied. However, despite the importance of rhythms for the sustenance of life, this aspect of NMDAR function remains poorly studied. Written by one of the world’s leading authorities on NMDA receptors, Biology of the NMDA Receptor brings together virtually all the players in this important field.

Neurochemical Aspects of Alzheimer's Disease provides a comprehensive overview of molecular aspects of risk factors, pathogenesis, biomarkers, and therapeutic strategies. The book focuses on molecular mechanisms and signal transduction processes associated with the pathogenesis, biomarkers, and therapeutic strategies of AD. The comprehensive and cutting edge information in this monograph may not only help in early detection of AD, but also promote discovery of new drugs to treat this chronic disease. Chapters discuss involvement of neural membrane phospholipids, sphingolipids, and cholesterol-derived lipid mediators, abnormal APP processing, and nucleic acid damage, risk factors, biomarker, and therapeutic strategies of Alzheimer's disease. This book is written for neurologists, neuroscientists, neurochemists, neuropharmacologists, and clinicianswho are interested in molecular mechanisms associated with the pathogenesis of age-related neurological disorders. Provides a comprehensive overview of molecular aspects of risk factors, pathogenesis, biomarkers, and therapeutic strategies for Alzheimer's disease Written for researchers, clinicians, and advanced graduate students in neurology, neuroscience, neurochemistry, and neuropharmacology Acts as the first book to provide a comprehensive description of the signal transduction processes associated with pathogenesis of Alzheimer's disease